NasdaqCM:AKBABiotechs
Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data
In the past week, Akebia Therapeutics reported third-quarter 2025 earnings, showing total revenue rising to US$58.77 million from US$37.43 million a year earlier and a net income swing to US$0.54 million compared to a net loss previously.
This robust financial turnaround was accompanied by new clinical data presented at ASN Kidney Week 2025, indicating Vafseo may offer dialysis patients a significantly reduced risk of death or hospitalization versus standard therapy.
We’ll explore how this...